Reunion Neuroscience has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug.
Beckley Psytech has announced a new clinical trial investigating its novel formulation of the psychedelic drug DMT for the treatment of depression.
COMPASS Pathways has presented new, positive data demonstrating the potential of COMP360 psilocybin therapy in depression at the Annual Meeting of the American College of Neuropsychopharmacology...
A team of researchers at the University of Pennsylvania School of Medicine have published findings which show how ketamine dramatically reorganises activity in the brain –...
Psyrise, a mental health marketing company located in South Florida, has released a first-of-its-kind marketing platform for health practitioners in the field of psychedelic therapies.
Irwin Naturals is branching into the psychedelics space with the aim of establishing the world’s largest chain of psychedelic mental health clinics.
A team at the Allen Institute for Brain Science, a division of the Allen Institute, has sent brain samples on a “trip” to gain insights into...
Biomind Labs has confirmed that it has had a Pre-Investigational New Drug (Pre-IND) meeting granted by the U.S.
Origin Therapeutics’ portfolio company, Xpira Pharmaceuticals, has received FDA approval for its Psilocybin Trial IND Application.
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.